| Not Yet Recruiting | Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study NCT07292272 | University of Nebraska | Phase 2 |
| Not Yet Recruiting | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML NCT07157514 | Actinium Pharmaceuticals | Phase 2 / Phase 3 |
| Recruiting | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia NCT06429449 | University of Colorado, Denver | Phase 1 |
| Recruiting | A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute NCT06235801 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML NCT05309018 | Centre Hospitalier Régional Metz-Thionville | — |
| Active Not Recruiting | Integrated Actionable Aging Assessment for Cancer Patients Pilot NCT05871008 | University of Colorado, Denver | N/A |
| Recruiting | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT NCT06130579 | Peking University People's Hospital | Phase 2 |
| Unknown | Frequency and Risk Factors of Acute Myeloid Leukemia NCT05787951 | Assiut University | — |
| Recruiting | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors NCT05194397 | Children's Hospital of Philadelphia | Phase 2 |
| Completed | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia NCT04714372 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in S NCT05363488 | Pfizer | — |
| Active Not Recruiting | Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors NCT05035706 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogen NCT04628338 | Sawa Ito, MD | EARLY_Phase 1 |
| Recruiting | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL NCT04260022 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients NCT03613727 | Virginia Commonwealth University | Phase 2 |
| Unknown | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies NCT03638206 | Shenzhen BinDeBio Ltd. | Phase 1 / Phase 2 |
| Completed | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery NCT02955043 | University of Wisconsin, Madison | N/A |
| Completed | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents NCT02763475 | Instituto de Investigación Hospital Universitario La Paz | Phase 2 |
| Unknown | Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron NCT03659084 | Hospices Civils de Lyon | — |
| Completed | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation NCT02719821 | University of Wisconsin, Madison | N/A |
| Unknown | Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacy NCT02489929 | Assistance Publique Hopitaux De Marseille | N/A |
| Completed | Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT NCT01779882 | University Hospital, Basel, Switzerland | N/A |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies NCT01643603 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Completed | Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia NCT01380756 | Amgen | Phase 1 |
| Unknown | Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predic NCT01066338 | Samsung Medical Center | — |
| Unknown | Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment NCT01066286 | Samsung Medical Center | — |
| Terminated | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) NCT00967343 | Kiadis Pharma | Phase 2 / Phase 3 |
| Terminated | Study of IMC-EB10 in Participant With Leukemia NCT00887926 | Eli Lilly and Company | Phase 1 |
| Terminated | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positi NCT00543972 | Sanofi | Phase 1 |
| Completed | Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Trans NCT00422890 | Technische Universität Dresden | Phase 3 |
| Completed | Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia NCT00497991 | AstraZeneca | Phase 1 |
| Terminated | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia NCT00126893 | Celgene Corporation | Phase 1 |
| Completed | A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups NCT00521664 | Technische Universität Dresden | Phase 3 |
| Unknown | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents NCT00111345 | University Hospital Muenster | Phase 2 / Phase 3 |
| Completed | Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) NCT00114764 | Amgen | Phase 2 |
| Completed | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malig NCT00001748 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Ad NCT00001637 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |